ACIP Recommendations

The ACIP develops recommendations on how to use vaccines to control disease in the United States.

The Committee’s recommendations are forwarded to CDC’s Director and once adopted become official CDC policy. These recommendations are then published in CDC’s Morbidity and Mortality Weekly Report (MMWR).

ACIP Recommendations
Complete list of ACIP recommendations published in the MMWR.
Immunization Schedules
Links to the childhood, adolescent, catch-up, and adult immunization schedules; plus vaccine recording and screening forms.
ACIP Shared Clinical Decision-Making FAQs
Frequently asked questions about ACIP’s recommendations based on shared clinical decision-making

Recent Meeting Recommendations

ACIP approved the following recommendations by majority vote and they have been adopted by the CDC Director. They will be published in MMWR and reflected in CDC’s print and digital resources in the coming months.

February 28-29, 2024
ACIP approved the following recommendation by majority vote at its February 28-29, 2024 meeting:

COVID-19 Vaccines

ACIP recommends persons ≥65 years of age should receive an additional dose of 2023–2024 Formula COVID-19 vaccine.

Chikungunya Vaccine

Recommendations for use of chikungunya vaccine among travelers:

ACIP recommends chikungunya vaccine for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak

In addition, chikungunya vaccine may be considered for the following persons traveling to a country or territory without an outbreak but with evidence of chikungunya virus transmission among humans within the last 5 years

Persons aged >65 years, particularly those with underlying medical conditions, who are likely to have at least moderate exposure* to mosquitoes, OR
Persons staying for a cumulative period of 6 months or more

*Moderate exposure could include travelers who might have at least 2 weeks (cumulative) of exposure to mosquitoes in indoor or outdoor settings

Recommendations for use of chikungunya vaccine among laboratory workers:

ACIP recommends chikungunya vaccine for laboratory workers with potential for exposure to chikungunya virus

These recommendations have been adopted by the CDC Director on February 28, 2024 and are now official.

October 25-26, 2023

Meningococcal Vaccines

Pfizer’s MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit.*

*1) Healthy individuals aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccination, 2) individuals aged 10 years and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for both vaccines.

Mpox Vaccines

ACIP recommends vaccination^*with the 2-dose^§ JYNNEOS vaccine series for persons aged 18 years and older at risk for mpox^¶

*This is an interim recommendation that ACIP will revisit in 2-3 years

^§Dose 2 administered 28 days after dose 1

^¶Persons at risk:

Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had one of the following:
- A new diagnosis of ≥1 sexually transmitted disease
- More than one sex partner
- Sex at a commercial sex venue
- Sex in association with a large public event in a geographic area where mpox transmission is occurring
Sexual partners of persons with the risks described in above
Persons who anticipate experiencing any of the above

Combined Immunization Schedules

Approve the Recommended Child and Adolescent Immunization Schedule, United States, 2024 and the Recommended Adult Immunization Schedule, United States, 2024.

These recommendations have been adopted by the CDC Director on October 26, 2023 and are now official.

February 22-24, 2023
ACIP approved the following recommendation by majority vote at its February 22-24, 2023 meeting:

ACIP recommends the 2-dose^* JYNNEOS vaccine series for persons aged 18 years and older at risk of mpox during an mpox outbreak^§.
^*Dose 2 administered one month after dose 1
^§Public health authorities determine whether there is an mpox outbreak; a single case may be considered an mpox outbreak at the discretion of public health authorities. Other circumstances in which a public health response may be indicated include ongoing risk of introduction of mpox into a community due to disease activity in another geographic area.

This recommendation has been adopted by the CDC Director and is now official.